Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. - Wikidata - awgldk - TriplyDB

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

http://www.wikidata.org/entity/Q35005912

about

Therapeutic cancer vaccines: using unique antigens B-Raf specific antibody responses in melanoma patients Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+ T cells T-cell clonotypes in cancer LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma T-cell-based immunotherapy of melanoma: what have we learned and how can we improve?DNA fusion gene vaccines against cancer: from the laboratory to the clinic.Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.Regulators of apoptosis: suitable targets for immune therapy of cancer.Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model Clinical development of Listeria monocytogenes-based immunotherapies.Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer.An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.Generating long-lived CD8(+) T-cell memory: Insights from epigenetic programs.Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.Advances in cellular therapy for the treatment of thyroid cancer.Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.Cancer vaccines: should we be targeting patients with less aggressive disease?Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients.Tracking antigen-specific CD8⁺ T cells using MHC class I multimers.Tumour susceptibility to innate and adaptive immunotherapy changes during tumour maturation.Modelling lymphoma therapy and outcome.Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.MAGE proteins regulate KRAB zinc finger transcription factors and KAP1 E3 ligase activity.Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.The detection of CMV pp65 and IE1 in glioblastoma multiforme.Immunity against mouse thymus-leukemia antigen (TL) protects against development of lymphomas induced by a chemical carcinogen, N-butyl-N-nitrosourea.Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.Cancer/testis antigen MAGE-A4 expression pattern differs in epithelial skin tumors of organ-transplant recipients and immunocompetent patients.Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.A polymorphism of the YTHDF2 gene (1p35) located in an Alu-rich genomic domain is associated with human longevity.

P2860

Q24563772-213A2757-9A9F-4382-B529-1DFC813E79DC Q24794587-C2DFE856-4A88-4971-A385-11ED3985577B Q24802970-E08D9FE0-9BCF-4D9B-AEC7-662B99E984C8 Q24803891-AF9C682E-485F-4C06-80F3-E68A9D5DF971 Q34111719-1EDA9AD0-DD5E-4B80-94D7-04ABB9C11C0F Q34722558-65723BBE-B37F-435C-8D69-F5FC42D70958 Q35728607-6456DECB-5A87-473D-AFCB-EA2649C249E0 Q35826392-49FD6EB8-F90D-4C28-822C-D980F129A995 Q35854237-673A90F9-A782-4DFC-95B7-4B549C21CDDA Q36111911-36968E86-6810-4643-B683-DA8328E7FC86 Q36459340-6C9E2EB1-92B6-4338-B27D-9221638B78FE Q36503123-9F527F97-5BA3-4457-AE1F-3FC8967095EE Q36615924-C3B2E197-C8C3-4DAB-A125-EB77DEC6DDAF Q36637039-DE369137-1530-46D6-AC5E-A0DB7144C5D4 Q36754562-78A854DC-15F8-4CB0-A4C7-205BDC87C190 Q37052200-4C44A462-7F73-4B1E-8F87-2B0F4DB46B5F Q37137360-FF1DEC5A-067C-48B8-93DB-B6195C086047 Q37273315-03067EEE-BD3C-4D73-BC4C-B0486C64C736 Q37280990-98E0DA2C-2297-4411-B239-39256582B909 Q37570169-0DF1B23F-02E0-443C-90E2-A33930B819D4 Q37776660-1A27FC00-05F7-47F2-A9BA-616BA91FB981 Q38029543-8E470B5F-5F52-4763-BDC1-616CFCDEF576 Q38032880-9A871D4C-631F-4217-BC8D-32B81C7E0A54 Q39091723-06E617D5-E472-483F-8132-FC47DDFD74EA Q39483297-5B957FF1-3FB2-4AA8-9302-9D6678C498F7 Q40505148-C0991F04-CAE0-4F81-9618-789C2F0F7BD4 Q41957184-621FDB2A-CB92-42A9-8FB5-E3780B958A2C Q42186944-E08784AB-41C2-4EC3-B28B-4590C70E4B22 Q42976839-5C9C5FD6-FE0F-4C86-856D-0A9976D43CC4 Q43867577-7C30F903-7E94-4F31-943B-8784FF289101 Q44004603-A5178DF0-8931-442B-97C8-784CBD1B9F21 Q45152350-68F8D8D5-E876-46CA-A9D9-DD8385EB0F7D Q46423517-876AD128-2CEC-4110-8A80-655F7DC0729B Q52885159-E94395B7-696E-44F1-AEA4-363B0B5C33EB Q53338076-9BAAC051-AE62-47AE-AD11-11EC079476E2 Q54405940-58F42B52-52BA-4D37-8EF2-36B0F25DD297 Q54595214-E3ABB1AB-52DE-4D50-9690-FBBCD913155C

P2860

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

http://www.wikidata.org/entity/Q35005912

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

@ast

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

@en

type

label

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

@ast

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

@en

prefLabel

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

@ast

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

@en

P1433

Q35005912-0BD4A4B3-23B9-4437-A3BC-FB12F7E9432A

P1476

Q35005912-9605CA0F-E6ED-4F3B-93A4-BCF88E800D1B

P2093

Q35005912-0BD59EAE-4D5C-439B-97CB-18B98EBF084E

Q35005912-0D956AEA-49A4-42CA-93AE-659E2A2BEB49

Q35005912-1AA41037-036A-4F7F-96B9-4F54B19C9699

Q35005912-1C7F9928-811A-4095-9421-5079EF370AE3

Q35005912-2472DB2E-C291-4B5B-AE50-A5DEE73D577E

Q35005912-44976712-FE73-4036-995B-BFDCE9628BD7

Q35005912-604F0257-A723-4945-B181-12F46069533F

Q35005912-7D8240CB-BEC0-401D-A9B2-D8C33B775AE1

Q35005912-8C98F160-5754-48A1-B674-142D10776E83

Q35005912-C6C01AC0-1CD4-4632-A50D-DA35F1EFA97E

P2860

Q35005912-067D8871-4D49-4B5B-B8D2-2C6E4FB0231C

Q35005912-2A6AC71D-3D31-43DA-A8FF-CF1400C4DB95

Q35005912-2D00F503-4CC2-4079-8BDC-8DC0F8B50F31

Q35005912-3B27158C-761D-4443-84C3-2BE158B2C117

Q35005912-3C1B823D-84A3-4CCA-80FF-DC046F77EFAC

Q35005912-4221963D-88DD-4B33-8A7E-D2B10F344F72

Q35005912-485BF06A-4BC9-48D6-92CA-4A6A87FF36C1

Q35005912-561E2FD6-CDC6-4CD8-9F5C-CBF4F3D5B224

Q35005912-5902EC62-9A76-4411-A3AB-5DD302DC8ADB

Q35005912-5BF66460-74D6-4831-B5B7-E36074C9DFD5

P304

Q35005912-77F76336-BC8A-4D1F-B925-DFD1E0BABCE2

P31

Q35005912-D9C21C2E-E38F-4EB0-9C71-01A19E25B46A

P356

Q35005912-6EE14608-D39C-4DC5-BDF5-676CB913706F

P478

Q35005912-3DE7F051-2CC7-4E91-9D0C-6E6F936B2A12

P50

Q35005912-B4BF3BB8-813E-415B-9E48-941C28E3300A

P577

Q35005912-2BF241B8-D069-4312-8858-0A1D4FB2264F

P698

Q35005912-96154BEA-D08E-4760-A7F3-E8BD65C9043E

P356

J.1600-065X.2002.18804.X

P1433

Immunological Reviews

P1476

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen

@en

P2093

Aline Van Pel

http://www.w3.org/2001/XMLSchema#string

Christophe Lonchay

http://www.w3.org/2001/XMLSchema#string

Christophe Lurquin

http://www.w3.org/2001/XMLSchema#string

Danièle Godelaine

http://www.w3.org/2001/XMLSchema#string

Didier Colau

http://www.w3.org/2001/XMLSchema#string

Marie Marchand

http://www.w3.org/2001/XMLSchema#string

Nicolas Van Baren

http://www.w3.org/2001/XMLSchema#string

Pierre G Coulie

http://www.w3.org/2001/XMLSchema#string

Takeshi Hanagiri

http://www.w3.org/2001/XMLSchema#string

Thierry Boon

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

LAGE-1, a new gene with tumor specificity

Phenotypic analysis of antigen-specific T lymphocytes

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.

P304

33-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1034/J.1600-065X.2002.18804.X

http://www.w3.org/2001/XMLSchema#string

P478

188

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12445279

http://www.w3.org/2001/XMLSchema#string